UDCA API Manufacturers and Suppliers Guide

Selecting the right UDCA (ursodeoxycholic acid) API manufacturer is a critical procurement decision for pharmaceutical formulators, generic drug developers, and regulatory affairs teams. This guide provides a data-driven overview of the global UDCA manufacturing landscape in 2026, compares ursodeoxycholic acid manufacturers by region and capability, and offers practical frameworks for evaluating UDCA suppliers across China, India, Europe, and Japan.

1. Global UDCA Manufacturing Landscape

Global UDCA API production reached approximately 1,647 tonnes in 2025, with the market valued at roughly $440 million. The manufacturing landscape is concentrated: the top 10 ursodeoxycholic acid manufacturers control an estimated 80% of global output, with production dispersed across four major regions, China, India, Europe (Italy, Germany, Latvia), and Japan/South Korea.

China is the single largest producing country by volume, contributing approximately 30% of global UDCA production (491 tonnes in 2025). Europe follows closely at 29% of global output, led by Italian manufacturers ICE Pharma, Dipharma Francis, and Erregierre. India accounts for roughly 18% of global production capacity, while Japan and South Korea together contribute the balance. However, revenue concentration tells a different story: Europe commands nearly 47% of global UDCA market revenue due to higher-value, fully regulatory-compliant API sales, while China's revenue share is approximately 7%, reflecting its position as a high-volume, lower-unit-price producer.

The supply chain begins with cholic acid extracted from bovine bile, a byproduct of the meat industry. China's structural advantage in UDCA manufacturing stems directly from the scale of its domestic beef industry (the largest globally by volume), which provides abundant, low-cost cholic acid starting material. European manufacturers rely on either imported cholic acid or synthetic routes. This raw material dynamic is a persistent factor in the competitive positioning of ursodeoxycholic acid manufacturers in different regions. For a deeper look at the chemistry and production process, see UDCA Complete Guide.

The market has grown at approximately 7% CAGR (API segment) and is forecast to reach $194-208 million by 2031-2032. Driving this growth are expanding therapeutic indications for UDCA (beyond primary biliary cholangitis and gallstone dissolution into NASH/NAFLD trials), rising liver disease prevalence globally, and growing generic drug penetration in developing markets.

2. Top UDCA API Manufacturers by Region

2.1 China: The World's Largest UDCA Producer

China is the dominant volume producer of UDCA API, with approximately 12 GMP-approved ursodeoxycholic acid manufacturers. The industry is highly concentrated: Zhongshan Belling Biotechnology, based in Guangdong, holds an estimated 48% domestic market share in China and accounts for approximately 74% of China's UDCA exports. The company recently expanded capacity from 280 to 420 tonnes/year and holds regulatory approvals from China NMPA, US FDA (following successful inspection), EDQM, and Japan's PMDA.

Other significant Chinese ursodeoxycholic acid API manufacturers include Changde Yungang (Hunan province, with approximately 480 tonnes/year nameplate capacity for bile acid products), Suzhou Tianlu Bio-Pharmaceutical (Jiangsu province, UDCA capacity approximately 80-160 tonnes/year, USP/EP/CP-grade, 13 patents), Sichuan Xieli Pharmaceutical, Linyi Tianli, and Jiangxi Shentian (approximately 30 tonnes/year). Several smaller steroid API manufacturers also produce UDCA, often on multi-purpose equipment shared with other bile acid derivatives.

Chinese UDCA API manufacturers benefit from vertically integrated production starting from domestic bovine bile extraction, a cost advantage that European and Indian competitors cannot easily replicate. However, pricing pressures from China's Volume-Based Procurement (VBP) policy and overcapacity have led to price moderation in 2024-2025. For procurement guidance specific to China sourcing, see How to Source UDCA from China.

2.2 India: Growing UDCA Manufacturing Capacity

India holds approximately 18% of global UDCA production capacity and is expanding rapidly. Arch Pharmalabs is the established domestic producer, accounting for over 80% of India's UDCA API output. The company successfully petitioned India's DGTR (Directorate General of Trade Remedies) for anti-dumping duties on UDCA imports from China and South Korea in 2022, reflecting its position as the dominant Indian manufacturer seeking trade protection.

Shilpa Medicare has emerged as a notable ursodeoxycholic acid API manufacturer, receiving a CEP from EDQM for Ursodeoxycholic Acid API in July 2024. Its subsidiary Shilpa Pharma Lifesciences also operates a joint venture (Raichem Medicare) with Italy's ICE Pharma, manufacturing advanced UDCA intermediates. Shilpa Medicare also achieved a first-in-class milestone with CDSCO approval for Nor Ursodeoxycholic Acid (NorUDCA) tablets for NAFLD, signaling deeper investment in the bile acid therapeutic space. Sun Pharmaceutical markets UDCA finished dosage forms internationally (brand Udihep) and represents approximately 10.6% of global UDCA market revenue by finished product sales.

India's competitive advantages include lower API manufacturing costs than Europe, a strong track record of DMF filings with the US FDA, and growing regulatory recognition. Indian ursodeoxycholic acid manufacturers are increasingly competing with Chinese suppliers on price while offering the advantage of English-language business communication and established pharmaceutical export infrastructure.

2.3 Europe: Italy and Spain-Based Producers

Europe accounts for approximately 29% of global UDCA production volume but commands 47% of global market revenue, reflecting the premium pricing that fully regulatory-compliant, Western-inspected API commands. Italy is the center of European UDCA manufacturing, home to three of the top 10 global ursodeoxycholic acid manufacturers.

ICE Pharma (Italy) is the largest European producer with an estimated 12.6% global market share and $15.2 million in 2024 revenue. Dipharma Francis (Italy) holds approximately 9.5% global share, and Erregierre (Italy) holds 7.4%. Outside Italy, Grindeks (Latvia) contributes 8.5% global share, and PharmaZell GmbH (Germany) holds 8.0%. These European manufacturers benefit from long-established relationships with EMA and EDQM, mutually recognized GMP inspections, and strong positions in the European finished dosage form supply chain.

European UDCA manufacturers typically focus on high-purity, EP-grade material with comprehensive regulatory documentation packages, serving branded and generic pharmaceutical companies in regulated markets. Their cost structure is higher than Chinese and Indian competitors, but their regulatory standing and audit history are well-established, making them preferred suppliers for risk-averse pharmaceutical companies launching products in the EU and North America.

2.4 Japan: Mitsubishi Tanabe and Others

Mitsubishi Tanabe Pharma (Japan) is the largest UDCA manufacturer globally by revenue, with an estimated 15.2% market share and $18.4 million in 2024 UDCA revenue. Its product lines include Urso API Ultra-Pure and UDCA Micro-90, serving customers including GSK, Abbott, and Takeda. The company expanded its Osaka plant capacity by 20% recently and signed multi-year supply agreements with major pharmaceutical partners. Mitsubishi Tanabe is known for best-in-class purity standards, though its unit costs are higher than those of Asian volume competitors.

Daewoong Pharmaceutical (South Korea) ranks third globally with an 11.6% market share and $14 million in revenue. Daewoong leverages proprietary fermentation technology for high-yield UDCA production and has recently filed a DMF with the US FDA, signaling intent to enter the North American API market. It operates a Vietnam distribution hub to serve Southeast Asian customers.

The Japan-Korea UDCA manufacturing segment is characterized by high product quality, strong intellectual property positions, and focus on branded and specialty generic markets in Asia-Pacific. These manufacturers serve as reference-quality benchmarks for the industry and are less likely to compete on price with volume-focused Chinese and Indian producers.

3. How to Evaluate UDCA API Manufacturers

Evaluating ursodeoxycholic acid manufacturers requires a structured, multi-dimensional assessment. The following framework covers the five critical evaluation dimensions for pharmaceutical procurement teams.

GMP Certification Status. Verify the specific GMP standard that applies. A Chinese NMPA GMP certificate covers domestic production but does not automatically satisfy FDA or EU requirements. For regulated markets, confirm whether the facility holds EU GMP certification (issued by an EU competent authority or MRA partner), has passed an FDA inspection with a VAI or NAI classification, or holds a valid CEP from EDQM. Request a copy of the current certificate, verify the issuing authority, confirm the facility name matches the production site, and check that UDCA is within the certified product scope. An expired certificate or one listing a different legal entity is of limited value.

DMF and CEP Filing Status. A US FDA Type II DMF in "active" status indicates the manufacturer has responded to the most recent FDA review cycle. However, an active DMF is not equivalent to a successful FDA inspection, the DMF review and the facility inspection are independent processes. A valid CEP from EDQM certifies compliance with the European Pharmacopoeia monograph and is the most straightforward evidence of EP compliance for EU marketing authorization. Verify both in public databases: the FDA DMF database for listing confirmation and the EDQM Certification database for CEP validity.

Production Capacity and Batch Consistency. Assess whether the manufacturer's annual UDCA output aligns with your volume requirements. A manufacturer producing 10 tonnes/year may struggle to supply a customer requiring 5 tonnes/year without disrupting other supply commitments. Request batch-to-batch impurity profile data for the last 10-20 production batches; consistent impurity profiles over time are the strongest indicator of process control. A manufacturer whose impurity levels drift toward specification limits across consecutive batches may have a process running at the edge of its capability.

Audit History and Regulatory Track Record. A manufacturer that has been inspected by multiple foreign regulatory authorities (FDA, EDQM, PMDA, ANVISA) or by third-party audit firms commissioned by multinational pharmaceutical customers demonstrates a quality system that meets diverse regulatory expectations. Check the FDA warning letter database, the EDQM suspension/cancellation list, and the EU GMP non-compliance database before committing to a supplier.

Supply Chain Transparency. Trace the manufacturer's cholic acid supply chain to the source. Manufacturers who can document the origin of their starting materials (bovine bile source, extraction facility, intermediate suppliers) demonstrate supply chain maturity. This is particularly important given that sporadic bovine disease outbreaks or trade restrictions on animal-derived materials can disrupt UDCA supply.

4. Comparison Table: UDCA Manufacturers by Capability

The following table compares the four main categories of UDCA suppliers in the global market as of 2026. This framework helps procurement teams identify which supplier type best fits their regulatory requirements, volume needs, and budget.

5. UDCA API Pricing Factors

UDCA API pricing is driven by a combination of raw material costs, manufacturing scale, pharmacopoeia grade, and regional market dynamics. Understanding these factors helps buyers benchmark supplier quotes and negotiate effectively.

Cholic Acid Raw Material Costs. The single largest variable in UDCA production cost is cholic acid starting material, which is extracted from bovine bile. China's domestic beef industry produces the world's largest volume of bovine bile as a slaughterhouse byproduct, giving Chinese manufacturers a structural raw material cost advantage. When global beef production fluctuates (due to drought, disease outbreaks, or trade restrictions), cholic acid prices shift, and UDCA API prices follow. European manufacturers that import cholic acid or use alternative synthetic routes face higher and more volatile input costs.

Production Scale. UDCA manufacturing economics favor scale. Large dedicated UDCA production lines with annual capacities of 100+ tonnes achieve significantly lower per-kilogram costs than multi-purpose facilities producing 10-30 tonnes/year. This is why the top five global ursodeoxycholic acid manufacturers (which control the majority of capacity) can offer pricing that smaller producers cannot match. However, the capacity expansion in China over 2022-2024 (notably Zhongshan Belling's increase to 420 tonnes/year and Changde Yungang's 480 tonnes/year nameplate) has created overcapacity, contributing to price softening in 2025-2026.

Pharmacopoeia Grade. EP-grade and USP-grade UDCA command pricing premiums over CP-grade product. The difference arises from stricter impurity specifications (EP requires chenodeoxycholic acid below 0.10% and lithocholic acid below 0.15%), more comprehensive residual solvent testing per ICH Q3C, and the additional quality system costs associated with maintaining EU GMP or FDA-inspected status. Expect EP-grade UDCA to price approximately 15-30% above CP-grade product from the same manufacturer.

Market Demand and Policy. Demand growth from expanding UDCA indications (PBC, NASH/NAFLD clinical trials) supports pricing, but countervailing pressures include China's Volume-Based Procurement policy, which pushes domestic UDCA prices downward, and generic drug penetration in Europe and North America, which compresses finished dosage form margins and cascades pricing pressure upstream to API suppliers. The net effect in 2025-2026 is moderate price softening, particularly for standard-grade UDCA from high-volume Chinese producers. For an indicative benchmark, India's 2022 anti-dumping investigation set minimum import prices for Chinese UDCA in the range of $424-455 per kilogram, though actual 2026 market pricing may differ.

6. Quality Standards: What to Look for in a UDCA Manufacturer

Pharmaceutical-grade UDCA must comply with one or more pharmacopoeia monographs: USP (United States Pharmacopeia), EP (European Pharmacopoeia), JP (Japanese Pharmacopoeia), or CP (Chinese Pharmacopoeia). The EP monograph (Ursodeoxycholic Acid, monograph 1275) and USP monograph (Ursodiol) are the most commonly referenced standards in international trade. A detailed comparison of these two standards is available in UDCA Quality Standards: USP vs EP Pharmacopoeia.

Assay and Identity. EP specifies 99.0-101.0% (anhydrous substance); USP specifies 98.0-102.0%. Both require identity confirmation by infrared absorption spectrophotometry and specific optical rotation (+58.0 to +62.0, anhydrous substance). These are standard parameters; any GMP manufacturer should meet them without difficulty.

Impurity Profile. The impurity profile distinguishes high-quality from marginal UDCA production. The critical related substances are chenodeoxycholic acid (CDCA, the 7-alpha epimer, EP limit below 0.10%), lithocholic acid (EP limit below 0.15%), and other unspecified impurities (EP limit below 0.10% each, total below 0.5%). Manufacturers with robust process control maintain CDCA and lithocholic acid levels well below the specification limits, typically at 0.02-0.05% across batches. A manufacturer whose CoA consistently shows CDCA at 0.08-0.10% (near the limit) may have an epimerization step running at its process capability boundary.

Residual Solvents. UDCA synthesis typically involves ethanol, methanol, acetone, or ethyl acetate as process solvents. ICH Q3C classifies these as Class 2 or Class 3 solvents with defined permissible daily exposures. EP limits ethanol to 5000 ppm or less. A UDCA CoA that lists residual solvents at or near the specification limits suggests inadequate drying or solvent recovery steps. For a comprehensive discussion, see our quality standards comparison.

Microbial Limits and Heavy Metals. Total aerobic microbial count (TAMC) should be 10^3 CFU/g or less, total yeast and mold count (TYMC) 10^2 CFU/g or less, and bile-tolerant gram-negative bacteria should be absent (EP requirement). Heavy metals should comply with ICH Q3D guidelines for elemental impurities. These parameters are less commonly problematic but should not be ignored; a sudden increase in microbial counts between batches can indicate facility hygiene issues.

GMP Compliance to ICH Q7. The ICH Q7 guideline (Good Manufacturing Practice for Active Pharmaceutical Ingredients) is the international standard. A manufacturer should be able to demonstrate compliance with all sections of ICH Q7 relevant to UDCA production, including quality management (Section 2), personnel (Section 3), facilities and equipment (Section 4), materials management (Section 7), production and in-process controls (Section 8), and laboratory controls (Section 11).

7. Why Choose KingWish as Your UDCA Supplier

KingWish is China's largest UDCA supplier, exporting 40+ metric tons annually to pharmaceutical manufacturers in over 100 countries. Our UDCA meets EP and USP standards and is manufactured in a GMP-certified facility in Zhongshan, Guangdong, the same manufacturing region that hosts China's top UDCA producers. We maintain full regulatory documentation support including FDA DMF and CEP filing authorization letters.

As a trading company with deep UDCA specialization, KingWish bridges the gap between Chinese manufacturing capacity and international pharmaceutical procurement requirements. Our model offers distinct advantages for overseas buyers:

• Quality Assurance. Every batch is accompanied by a full documentation package: Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), GMP certificates, and DMF/CEP authorization letters. We verify documentation before shipment, providing an additional quality gate beyond the manufacturer's own release process.
• Flexible Order Sizes. While direct UDCA manufacturer MOQs typically start at 25-50 kg, KingWish can accommodate evaluation orders as low as 1-5 kg from consolidated stock, enabling initial quality assessment and stability testing before committing to commercial volumes.
• Regulatory Support. We assist customers with DMF authorization letters, CEP access, technical dossiers, and responses to regulatory queries, drawing on years of experience supporting ANDA and MAA filings across multiple jurisdictions.
• Supply Security. With 40+ MT/year supply volume, we maintain buffer stock and multiple manufacturer relationships to mitigate single-source supply disruption risk.
• Logistics and Documentation. Full export documentation, including Certificate of Origin, commercial invoice, packing list, and bill of lading/airway bill. We manage shipment from factory to destination port under CIF, FOB, or CPT Incoterms.

Related Resources